Linklaters advised consortium banks, led by JP Morgan as Global Coordinator, in the successful IPO of Swiss biotechnology company Molecular Partners. The proposition also included an offer to institutional investors in the United States.

The offer price for the shares was 22.40 Swiss francs per share, representing a market capitalization of around 485 million Swiss francs. Listing of the shares of Molecular Partners and the first day of trading on the SIX Swiss Exchange took place on November 5, 2014.

The consortium banks were advised by a Linklaters team led by Dr Marco G. Carbonare (Capital Markets, Frankfurt). Other team members included Yohan Liyanage (Intellectual Property, London), Gabriel Grossman, Shane Milam (both US Tax, London), David Santoro, Daria Latysheva, Maria Maulhardt, Charles Eypper (all Capital Markets, Frankfurt) and Tommy Chen (Intellectual Property, London).